Implanet announces that it has been definitively granted intellectual protection for its JAZZ technology in Europe

Regulatory News:

IMPLANET (Paris:IMPL)(Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces that it has been definitively granted intellectual protection for its JAZZ technology in Europe until 2031 (under patent number EP 2521500).

A major milestone regarding the continuation of the Company’s innovation strategy, this patent applies to the entire JAZZ system and definitively secures full protection of the implant’s technical characteristics.

Ludovic Lastennet, CEO of Implanet, says: "This announcement validates the excellent upstream work accomplished by our Research and Development team to put in place long-term barriers to entry, by significantly reducing any possible attempts to develop a rival product. We can now capitalize on this patent to accelerate JAZZ’s transformation into a technological platform comprising a comprehensive range of implants covering 100% of our market. Our highly-promising portfolio of innovations will enable us to rapidly meet the demands of the entire spine surgeon community.”

About IMPLANET

Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surge Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2014 sales of €7.0 million. For further information, please visit www.implanet.com.

IMPLANET is listed on Compartment C of Euronext™ Paris.
Ticker: IMPL - ISIN code: FR0010458729